GlassScriptPhysician profile
Ann M Mcdermott
NPI 1437109204
$2,233.47
in general payments reported to CMS, 2019-2025
28 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.16 · 2020: $22.37 · 2021: $188 · 2022: $499 · 2023: $494 · 2024: $537 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,438.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $503.77 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $222.89 | 2022-2024 | |
| Pfizer INC. | $163.26 | 2019-2023 | |
| Dexcom, INC. | $157.51 | 2021-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $155.13 | 2021-2025 | Shingrix, Arexvy |
| Abbott Laboratories | $117.53 | 2022-2025 | Freestyle Libre 3, Thoratec Heartmate 3 Lvas Implant Kit, Eterna |
| Lilly USA, LLC | $110.24 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $92.89 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $74.59 | 2021-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Bayer Healthcare Pharmaceuticals INC. | $71.57 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $67.99 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $63.78 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $54.60 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.94 | 2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $40.94 | 2024-2025 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $30.66 | 2021-2022 | |
| Biogen, INC. | $28.63 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $26.51 | 2022 | |
| Amgen INC. | $26.09 | 2025 | Repatha |
| Exact Sciences Corporation | $24.45 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.78 | 2024 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $22.54 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $22.00 | 2024 | Farxiga |
| Seqirus USA INC | $21.46 | 2025 | Flucelvax, Fluad |
| Hologic Sales and Service, LLC | $20.24 | 2025 | Acessa Provu System |
| Lundbeck LLC | $15.69 | 2024 | Rexulti |
| Cranial Technologies, INC | $15.59 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.20 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Mcdermott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.